MedTrace Logo

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

NCT01334879 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-10-02

No results posted yet for this study

Summary

This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.

Conditions

  • Radiation Retinopathy

Interventions

DRUG

ranibizumab 2.0 mg

Intravitreal ranibizumab (2.0 mg)

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • The New York Eye Cancer Center

    lead OTHER

Principal Investigators

  • Paul T Finger, MD · The New York Eye Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334879 on ClinicalTrials.gov